Rein Therapeutics, Inc. Proceeds from Issuance of Redeemable Convertible Preferred Stock
Rein Therapeutics, Inc. (RNTX) reported Proceeds from Issuance of Redeemable Convertible Preferred Stock of $471.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock · last filed 2018-04-02
- Rein Therapeutics, Inc. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2017-09-30 was -$1.00K.
- Rein Therapeutics, Inc. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2016-09-30 was $0.00.
| Period end | Proceeds from Issuance of Redeemable Convertible Preferred Stock 1 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 3 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 6 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 9 month |
|---|---|---|---|---|
| 2017-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $471.00K 10-Q · filed 2017-11-09 | ||
| 2017-06-30 | $472.00K 10-Q · filed 2017-08-10 | |||
| 2017-02-28 | $626.00K 10-K · filed 2018-04-02 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $13.18M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $13.18M 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |